1074 related articles for article (PubMed ID: 28233086)
21. Prognostic value of pretreatment PET/CT lean body mass-corrected parameters in patients with hepatocellular carcinoma.
Sun M; Zhang G; Guo J; Hao S; Wang Z; Fan G
Nucl Med Commun; 2018 Jun; 39(6):564-571. PubMed ID: 29634658
[TBL] [Abstract][Full Text] [Related]
22. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V;
Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
[TBL] [Abstract][Full Text] [Related]
23. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis.
Padia SA; Alessio A; Kwan SW; Lewis DH; Vaidya S; Minoshima S
J Vasc Interv Radiol; 2013 Aug; 24(8):1147-53. PubMed ID: 23792126
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Baseline
Wu M; Wang Y; Yang Q; Wang X; Yang X; Xing H; Sang X; Li X; Zhao H; Huo L
J Nucl Med; 2023 Oct; 64(10):1532-1539. PubMed ID: 37500263
[TBL] [Abstract][Full Text] [Related]
25. Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer.
Sabet A; Meyer C; Aouf A; Sabet A; Ghamari S; Pieper CC; Mayer K; Biersack HJ; Ezziddin S
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):370-6. PubMed ID: 25351506
[TBL] [Abstract][Full Text] [Related]
26.
Sung PS; Park HL; Yang K; Hwang S; Song MJ; Jang JW; Choi JY; Yoon SK; Yoo IR; Bae SH
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):384-391. PubMed ID: 29124280
[TBL] [Abstract][Full Text] [Related]
27. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis.
Lee JW; Yun M; Cho A; Han KH; Kim DY; Lee SM; Lee JD
Ann Nucl Med; 2015 Jun; 29(5):400-8. PubMed ID: 25652647
[TBL] [Abstract][Full Text] [Related]
28. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
[TBL] [Abstract][Full Text] [Related]
29. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
30. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
[TBL] [Abstract][Full Text] [Related]
31. [Value of (18)F-FDG PET in preoperative TACE of hepatocellular carcinoma].
Chang Z; Song P; Wang M; Liu F; Duan F; Wang Z; Wang Y
Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):377-81. PubMed ID: 25030595
[TBL] [Abstract][Full Text] [Related]
32. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
[TBL] [Abstract][Full Text] [Related]
33. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
[TBL] [Abstract][Full Text] [Related]
34. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
[TBL] [Abstract][Full Text] [Related]
36. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
[TBL] [Abstract][Full Text] [Related]
37. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study.
Abdallah MA; Wongjarupong N; Hassan MA; Taha W; Abdalla A; Bampoh S; Onyirioha K; Nelson M; Glubranson LA; Wiseman GA; Fleming CJ; Andrews JC; Mahipal A; Roberts LR
Expert Rev Gastroenterol Hepatol; 2020 Jul; 14(7):619-629. PubMed ID: 32490691
[TBL] [Abstract][Full Text] [Related]
38. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers.
Takeuchi S; Rohren EM; Abdel-Wahab R; Xiao L; Morris JS; Macapinlac HA; Hassan MM; Kaseb AO
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):969-978. PubMed ID: 27942837
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of
Lim CH; Moon SH; Cho YS; Choi JY; Lee KH; Hyun SH
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1705-1712. PubMed ID: 31049603
[TBL] [Abstract][Full Text] [Related]
40. 18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma.
Song MJ; Bae SH; Lee SW; Song DS; Kim HY; Yoo IeR; Choi JI; Lee YJ; Chun HJ; Lee HG; Choi JY; Yoon SK
Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):865-73. PubMed ID: 23436073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]